PMID- 25832955
OWN - NLM
STAT- MEDLINE
DCOM- 20150914
LR  - 20220410
IS  - 1349-7235 (Electronic)
IS  - 0918-2918 (Linking)
VI  - 54
IP  - 7
DP  - 2015
TI  - Central nervous system manifestations of tuberculosis-associated immune 
      reconstitution inflammatory syndrome during adalimumab therapy: a case report and 
      review of the literature.
PG  - 847-51
LID - 10.2169/internalmedicine.54.2828 [doi]
AB  - A 64-year-old neurologically asymptomatic woman with rheumatoid arthritis who was 
      treated with the tumor necrosis factor (TNF)-alpha antagonist adalimumab developed 
      disseminated tuberculosis (TB). After receiving anti-TB therapy and discontinuing 
      adalimumab, she exhibited paradoxical worsening due to immune reconstitution 
      inflammatory syndrome (IRIS) with the appearance of meningitis and brain 
      tuberculomas. This case indicates that continuing anti-TNF therapy may be 
      necessary to prevent IRIS in patients who develop TB, particularly disseminated 
      TB, during the course of anti-TNF therapy. In addition, careful screening for 
      central nervous system (CNS) TB should be performed prior to the initiation of 
      therapy, as even neurologically asymptomatic patients can develop CNS 
      manifestations of IRIS.
FAU - Tanaka, Toru
AU  - Tanaka T
AD  - Department of Respiratory Medicine, National Hospital Organization, 
      Ibarakihigashi National Hospital; 2 Department of Pulmonary Medicine and 
      Oncology, Graduate School of Medicine, Nippon Medical School, Japan.
FAU - Sekine, Akimasa
AU  - Sekine A
FAU - Tsunoda, Yoshiya
AU  - Tsunoda Y
FAU - Takoi, Hiroyuki
AU  - Takoi H
FAU - Lin, Shin-Yuan
AU  - Lin SY
FAU - Yatagai, Yohei
AU  - Yatagai Y
FAU - Hayasihara, Kenji
AU  - Hayasihara K
FAU - Saito, Takefumi
AU  - Saito T
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Review
DEP - 20150401
PL  - Japan
TA  - Intern Med
JT  - Internal medicine (Tokyo, Japan)
JID - 9204241
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Antitubercular Agents)
RN  - FYS6T7F842 (Adalimumab)
SB  - IM
MH  - Adalimumab
MH  - Anti-Inflammatory Agents/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized/*therapeutic use
MH  - Antirheumatic Agents/therapeutic use
MH  - Antitubercular Agents/therapeutic use
MH  - Arthritis, Rheumatoid/drug therapy
MH  - Female
MH  - Humans
MH  - Immune Reconstitution Inflammatory Syndrome/*prevention & control
MH  - Magnetic Resonance Imaging
MH  - Middle Aged
MH  - Tomography, X-Ray Computed
MH  - Tuberculoma, Intracranial/*prevention & control
MH  - Tuberculosis, Meningeal/*prevention & control
MH  - Tuberculosis, Miliary/drug therapy
EDAT- 2015/04/04 06:00
MHDA- 2015/09/15 06:00
CRDT- 2015/04/03 06:00
PHST- 2015/04/03 06:00 [entrez]
PHST- 2015/04/04 06:00 [pubmed]
PHST- 2015/09/15 06:00 [medline]
AID - 10.2169/internalmedicine.54.2828 [doi]
PST - ppublish
SO  - Intern Med. 2015;54(7):847-51. doi: 10.2169/internalmedicine.54.2828. Epub 2015 
      Apr 1.